Madeline Kennedy describes the benefits of a multidisciplinary care approach for people living with ALS.
Trial News & Events
Please join us on March 23rd for a webinar discussion on cannabinoid use in ALS led by Drs. Mark Ware and Angela Genge from the Montreal Neurological Institute and Hospital. Dr. Ware will discuss the mechanism of action of cannabinoids, while Dr. Genge will discuss their use in symptom management, and possible effect on disease course.
Barrow Neurological Institute is seeking individuals to participate in a remote research study called ALS AT HOME, enrolling under the direction of Dr. Jeremy Shefner.
NEALS is pleased to announce a full day training session for NEALS investigators interested in developing and conducting multi-center ALS clinical trials as Principal Investigators.
Neuraltus Pharmaceuticals, Inc., is currently enrolling up to 120 individuals with ALS and evidence of systemic inflammation in a second Phase 2 study of its investigational treatment NP001, an immune system regulator.
At the 6th Annual Les Turner Symposium on ALS and NeuroRepair, sponsored by the Les Turner ALS Research and Patient Center at Northwestern Medicine held in November 2016, a crowd of over 175 attendees learned the latest in ALS research and patient care from experts in the field.
Join Genetic Counselor and Assistant Professor at The Ohio State Wexner Medical Center, Jennifer Roggenbuck, on January 20th at 2:00 PM EST for a live webinar to learn more about genetic testing in ALS.
2015 NEALS Research Ambassador, Dexter Ang, was awarded the ALS Assistive Technology prize by The ALS Association and Prize4Life during this year's ALS/MND International Alliance Meeting.
Over 53 NEALS members authored posters presented at the 27th International Symposium on ALS/MND; 8 members chaired plenary sessions and 15 NEALS members presented platform presentations.
ALS Association Partnership to Fund RNS60 Treatment Trial with Biomarkers to Measure Neuroinflammati
The ALS Association, in partnership with ALS Finding a Cure and the Northeast ALS Consortium (NEALS), is pleased to announce $1 million in funding to support a new ALS clinical trial to test the efficacy of the experimental drug RNS60 in reducing inflammation that may hasten the disease process.